Regarding “Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma”

Regarding “Yttrium-90 Radioembolization for Unresectable Combined... Cardiovasc Intervent Radiol (2017) 40:1479 DOI 10.1007/s00270-017-1707-0 LETTE R T O T HE EDI T OR Regarding ‘‘Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma’’ Zhongzhi Jia Received: 22 April 2017 / Accepted: 19 May 2017 / Published online: 26 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 We read with great interest the recent article by Chan et al. may bias the results. Secondly, there were a total of 3 [1]. The authors concluded that radioembolization with patients with macrovascular invasion according to Table 1, yttrium-90 microspheres appears to be a promising treat- but there were 4 patients with macrovascular invasion ment option for patients with unresectable combined hep- according to Figure 2B, which causes serious confusion to atocellular–cholangiocarcinoma, and poor performance the readers. status and the presence of macrovascular invasion were Compliance with Ethical Standards identified as predictors of reduced survival after radioem- bolization. However, we would like to elaborate on the Conflicts of interest The author declares that he has no competing treatments pre- and post-radioembolization of the patients. interests. Firstly, there were a total of 10 patients included in this study, and many of them had received wide-ranging ther- apies pre- and post-radioembolization, including References chemotherapy, hepatectomy, and TACE. In particular, patients 7 and 10 had chemorefractory hepatocellular– 1. Chan LS, Sze DY, Poultsides GA, et al. Yttrium-90 radioem- cholangiocarcinoma with macrovascular invasion, and both bolization for unresectable combined hepatocellular–cholangio- of them had not received any treatment after radioem- carcinoma. Cardiovasc Intervent Radiol. 2017. doi:10.1007/ bolization even though with stable disease, all of which s00270-017-1648-7. & Zhongzhi Jia Department of Interventional Radiology, No. 2 People’s Hospital of Changzhou, Nanjing Medical University, Xing Long Road 29#, Changzhou 213003, China CardioVascular and Interventional Radiology Springer Journals

Regarding “Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma”

1 page

Loading next page...
1 Page
Springer US
Copyright © 2017 by Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Medicine & Public Health; Imaging / Radiology; Cardiology; Nuclear Medicine; Ultrasound
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial